• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe

    11/14/23 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OTLK alert in real time by email

    ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced the appointment of Jedd Comiskey as Senior VP – Head of Europe.

    Mr. Comiskey has a successful track record in the planning, organization and execution of product launches. Over the course of his career, he has demonstrated innovative, solution-focused results, navigating the highly complex European pharmaceutical landscape.

    "We believe in the potential of ONS-5010 to address the global need for an approved bevacizumab that meets ophthalmic standards for the treatment of wet AMD. While continuing our efforts to meet the additional requirements that the FDA is requiring for U.S. approval of ONS-5010, we are working toward the upcoming decision date for our Marketing Authorization Application (MAA) in Europe with the EMA, expected in the first half of 2024. We believe Jedd will play an integral role as we prepare for a potential European partnership in launching ONS-5010," commented Russell Trenary, President and CEO of Outlook Therapeutics.

    Mr. Comiskey added, "I am thrilled to join the Outlook Therapeutics team to help solidify the Company's global launch strategy, and I believe ONS-5010 has the potential to be a meaningful treatment option in the ophthalmology landscape in Europe. As the Company continues its work towards potential European launch, I look forward to leveraging the valuable experience and proven approaches I've executed over my career to enable us to hit the ground running."

    Prior to joining Outlook Therapeutics, Jedd served as the Senior Brand Director; Ophthalmology at Apellis Switzerland GmbH. As part of his role, Jedd was the commercial lead for the launch of SYFOVRE® (pegcetacoplan), defining regional brand strategy, formulating key market commercialization plans, engaging stakeholders, and supporting affiliates with launch preparations. In addition to his regional role, Jedd was accountable for detailed mapping of the ophthalmology landscape, preparatory stakeholder engagement and formulation of comprehensive commercialization strategy, and infrastructure plans at Apellis. Prior to that, Jedd served as the Franchise Head GI Rare at Takeda Pharmaceuticals International AG where he was responsible for directing the company's commercial launch across Europe and Canada for two treatments indicated for rare gastrointestinal disorders. He also served as the Director of Market Access and Marketing at Takeda Products Ireland Ltd. Additional career appointments include Head of Market Access at Bayer Ltd, Market Access Manager at Takeda Products Ireland Ltd, Product Manager: ADHD at Shire Pharmaceuticals Ireland Ltd, and Cardiovascular Product Manager at Servier Laboratories Ireland Ltd.

    Mr. Comiskey holds a Bachelor of Science in Chemistry from the University College Dublin and a PhD in Chemistry from the Royal College of Surgeons in Ireland.

    About Outlook Therapeutics, Inc.

    Outlook Therapeutics is a biopharmaceutical company working to achieve FDA approval for the launch of ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics' BLA submission for ONS-5010 to treat wet AMD with an initial PDUFA goal date of August 29, 2023; the FDA did not approve the BLA during this review cycle and the Company is working with the FDA to address the issues that have been raised so that the BLA may be re-submitted. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company's multi-year commercial planning process, Outlook Therapeutics and Cencora, formerly AmerisourceBergen, entered into a strategic commercialization agreement to expand the Company's reach for connecting to retina specialists and their patients. Cencora will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services and other services in the United States. For more information, please visit www.outlooktherapeutics.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "may," "might," "intend," "potential," "predict," "should," or "will," the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements about ONS-5010's potential as the first FDA-approved ophthalmic formulation of bevacizumab-vikg, expectations concerning our ability to remediate or otherwise resolve deficiencies identified in the Complete Response Letter issued by the FDA, expectations concerning decisions of regulatory bodies, including the FDA and the EMA, and the timing thereof, plans for potential commercial launch of ONS-5010, expectations concerning our relationship with AmerisourceBergen and the benefits and potential expansion thereof and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by the FDA, as well as those risks detailed in Outlook Therapeutics' filings with the Securities and Exchange Commission (the "SEC"), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2022 as supplemented by the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, in each case as filed with the SEC and future quarterly reports we file with the SEC, which include the uncertainty of future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflict, high interest rates, inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

    CONTACTS:

    Media Inquiries:

    Harriet Ullman

    Vice President

    LaVoieHealthScience

    T: 617.429.5475

    [email protected]

    Investor Inquiries:

    Jenene Thomas

    Chief Executive Officer

    JTC Team, LLC

    T: 833.475.8247

    [email protected]



    Primary Logo

    Get the next $OTLK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTLK

    DatePrice TargetRatingAnalyst
    8/29/2025Buy → Neutral
    H.C. Wainwright
    8/28/2025Buy → Neutral
    Guggenheim
    12/2/2024Buy → Neutral
    Chardan Capital Markets
    3/27/2024$50.00Neutral → Buy
    BTIG Research
    2/15/2024$3.00Neutral → Buy
    Chardan Capital Markets
    1/25/2024Neutral → Buy
    Guggenheim
    12/27/2023$5.00Equal Weight → Overweight
    CapitalOne
    8/31/2023$5.00 → $1.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $OTLK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kenyon Lawrence A bought $28,446 worth of shares (5,000 units at $5.69), increasing direct ownership by 529% to 5,946 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    9/30/24 4:53:23 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Syntone Ventures Llc bought 714,286 shares, increasing direct ownership by 72% to 1,705,438 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    4/17/24 8:21:17 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Haddadin Yezan Munther bought $22,242 worth of shares (1,882 units at $11.82), increasing direct ownership by 59% to 5,049 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    3/29/24 10:39:09 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

    ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris. Details for the presentations are as follows: Session: VEGF Related and Other Retinal Indications Title: Optimising the treatment of retinal diseasePresenter: Bob Jahr, Chief Executive Officer of Outlook TherapeuticsDate and Time: Wednesday, September 3, 2025, 16:10 PM CEST / 10:10 AM EDT For more inf

    9/3/25 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Requests Type A Meeting with FDA

    ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. In the FDA's recently issued CRL, although the Agency acknowledged the NORSE TWO pivotal trial met its safety and efficacy endpoint

    9/2/25 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

    FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency's issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its biologics license application (BLA) resubmission, indicating that the FDA cannot approve the application in its present form for the treat

    8/28/25 6:30:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Outlook Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Outlook Therapeutics from Buy to Neutral

    8/29/25 8:20:01 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Outlook Therapeutics from Buy to Neutral

    8/28/25 12:48:22 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Outlook Therapeutics from Buy to Neutral

    12/2/24 10:06:30 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    SEC Filings

    View All

    Outlook Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    9/5/25 5:00:49 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    9/2/25 5:00:49 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Outlook Therapeutics Inc.

    SCHEDULE 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    8/14/25 5:15:38 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Jahr Robert Charles

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    7/9/25 5:17:49 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Jahr Robert Charles

    3 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    7/9/25 5:16:55 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sukhtian Ghiath M. was granted 4,285,714 shares (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    5/28/25 5:20:21 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    Financials

    Live finance-specific insights

    View All

    $OTLK
    Leadership Updates

    Live Leadership Updates

    View All

    $OTLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

    FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency's issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its biologics license application (BLA) resubmission, indicating that the FDA cannot approve the application in its present form for the treat

    8/28/25 6:30:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

    First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in EuropeONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the third quarter of fiscal year 2025 and provided a corporate update. Financial Highlights for the Fiscal Third Quarter Ended June 30, 2025For the fiscal third quarter ended June 30, 2025, Outlook Therapeutics reported net

    8/14/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

    LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 and provided a corporate update. "Outlook Therapeutics remains on track in 2025 to transform into a commercial-stage company with the planned upcoming commercial launch of LYTENAVA™ (bevaciz

    5/15/25 4:01:00 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

    Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chie

    7/1/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

    ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role from Randy Thurman, who will remain on the Board as Lead Independent Director. "On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest

    1/31/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics® Announces Executive Leadership Transition

    ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company's President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO. "On behalf of our management team

    12/3/24 4:30:00 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/14/24 4:55:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/7/24 4:17:05 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Outlook Therapeutics Inc. (Amendment)

    SC 13D/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    4/17/24 9:38:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care